DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma. Alam SK, Zhang Y, Wang L, Zhu Z, et al. Oncogene 2022;41:83-98.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Alam SK, Zhang Y, Wang L, Zhu Z, et al. DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma. Oncogene 2022;41:83-98.
PMID: 34675407